Who Attends
The program is designed for all size pharma/biotech companies, academia and investors seeking to enable a patient’s immune system to eradicate cancer.
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/cb000d90abd9777b19284a8c970889984e9265e1/Copy of Podd Pie Chart (1).png)
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/65490a0782d764a78ee0b4e9ac1aba6a144963b5/IO 360 2024 Day 2--206.jpg)
Biopharma Responsible for
- Cancer Immunotherapy
- Immuno-Oncology
- R&D Innovation & Strategy
- Clinical R&D
- Business Development
- Preclinical and Translational Research
- Biomarkers and Companion Dx
- Early Stage Collaborations
- Clinical Operations
- Strategic Partnerships
- External R&D
- Licensing & Commercial Strategy
Solution Providers
- Diagnostic Testing
- Biomarkers and Companion Dx
- Assay Development
- Next Gen Sequencing
- mRNA / DNA Nucleic Acid Processing
- RNA Sequencing
- Cell Analysis/Manufacturing Platforms
- Liquid Biopsies
- Cancer Genetics
- Immune Monitoring
- Imaging Services
- Flow Cytometry
- Data Analysis/Analytics
- Laboratory Services
- Artificial Intelligence
- CROs/Clinical Trial Design
Investment Community Including
- Investment Firms
- Banks/Financial Institutions
- Venture Capital
- Private Equity
- Foundation Capital
- Analysts
Academia & Research Organizations Focusing on
- Immuno-Oncology / Cancer Immunotherapy
- Oncology
- Immunology
- Cancer Vaccines
- Adoptive T-Cell Therapy
- Preclinical & Clinical R&D
Professionals working in immuno-oncology business units will also benefit.
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/4b31aaa8701c6c99ca2df35e8c89dd7b8368428e/new documents created (2).png)
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/8ab31938d3470f7227de10471dd29e35fff4f953/1,286.jpg)
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/b2b42c6b6d5573eda4e21346959f33b4f012386d/new documents created (3).png)
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/baeadd5025670704d70c8e72f0edc1f7126af914/new documents created (9).png)
"IO360° was one of the best immuno-oncology meetings I’ve been to. Kudos! Great speakers and great dialogue!"
- Jim Mansfield, PerkinElmer
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/18fb549df8985910f2aa307a9f1c753819561a5e/IO 360 2024 Day 2-192.jpg)
IO360˚ is a strategic-level conference where Pharma and Biotech present along with academia and investors and hold partnering meetings so as a community we can drive faster advancements to eradicate cancer.
Immuno-Oncology 360° delivers three key benifits:
1. Access to KOLs driving the science
2. Partnership opportunities with all stakeholders in Immuno-Oncology
3. Presentations on the latest data affecting the science, clinical and business advancements in Immuno-Oncology
IO360° offers unparalleled business development and networking opportunities including:
Partnering/One-on-One Meetings:
• Dedicated partnering tables to connect with fellow industry professionals, investors and KOLs
• Partnering tool to schedule partnering meetings
• Meeting times occur throughout all breaks, lunches and receptions
• Set up multiple meetings per day
• Search other attendee profiles
• Send private message to other attendees
• Dedicated partnering help desk
Scheduled Networking:
IO360° networking opportunities take place throughout the entire event including:
• Scheduled morning and afternooon breaks
• Lunches
• Two receptions
• Access to the Exhibit hall
• Early evening organized historical walks of downtown Brooklyn
![](https://d38uvx7mib76ry.cloudfront.net/public/images/93c9600f9b054f306811eebf961057b56fbde5b7/IO 360 2024 Day 1-917.jpg)
![](https://d38uvx7mib76ry.cloudfront.net/public/images/1a8419b890ff2057bee153d6485c96497459055d/IO 360 2024 Day 2-802.jpg)